AstraZeneca could buy Bristol's diabetes stake for more than $3B, report says

12/19/2013 | Reuters

Bristol-Myers Squibb reportedly is considering divesting to partner AstraZeneca its stake in their diabetes joint venture for more than $3 billion. The venture includes oral drugs Onglyza, Kombiglyze and Forxiga as well as injectable treatments Bydureon and Byetta, this article says. Neither firm commented on the report.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC